

Kemwell appoints Dr Ninad Deshpanday as new President R&D

15 February 2013 | News | By BioSpectrum Bureau

Kemwell appoints Dr Ninad Deshpanday as new President R&D



Kemwell Biopharma, a global pharmaceutical contract development and manufacturing company, announced that it has appointed Dr. Ninad Deshpanday as President of Research and Development.

About the appointment, Anurag Bagaria, Chairman and Managing Director of Kemwell said, "Dr. Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia. He will spearhead the R&D business for Kemwell as we continue to grow the geographical footprint and strategically position Kemwell into a leading Global Contract Services Provider."

Dr. Deshpanday has over 22 years' experience of diverse international experience in the pharmaceutical industry (US + India). This includes pharmaceutical development activities for NDAs, specialty drug delivery based 505(b)(2) products, including Oral and Transdermal, and complex Generic products, with several F2Fs and PIVs. He also has rich experience in Technical and Business Development

Prior to joining Kemwell, he was President of Pharmaceutical R&D at Lupin, in Pune, India since November 2007, with leadership responsibilities for formulations, analytical, and BA/BE activities. Before joining Lupin, Dr. Deshpanday was Vice President of Business Development at AAI Pharma in RTP, NC, with responsibilities for sales and marketing activities for their CM&C functions; Vice President for Drug Product Development for Synta Pharmaceuticals, with responsibilities for all CM&C activities; and Technical Business Director for the Pharmaceuticals division of Cardinal Health. Dr. Deshpanday earned his Doctorate in Pharmaceutics from the University of S. Carolina in 1990, and has an M. Pharm. and B. Pharm. from LM College of Pharmacy in Ahmedabad, India.